Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study

D. Mahalingam, M. R. Patel, J. C. Sachdev, L. L. Hart, N. Halama, R. K. Ramanathan, J. Sarantopoulos, X. Liu, S. Yazji, D. Jäger, M. Yoon, G. Manzur, D. Adib, R. Kerschbaumer, A. Tsimberidou

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)vi116
JournalAnnals of Oncology
Volume27
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Mahalingam, D., Patel, M. R., Sachdev, J. C., Hart, L. L., Halama, N., Ramanathan, R. K., Sarantopoulos, J., Liu, X., Yazji, S., Jäger, D., Yoon, M., Manzur, G., Adib, D., Kerschbaumer, R., & Tsimberidou, A. (2016). Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study. Annals of Oncology, 27, vi116. https://doi.org/10.1093/annonc/mdw368.08